Ob/gyns are on the front line of the opioid epidemic and have a responsibility to recognize, treat, refer, and advocate for pregnant women with opioid use disorder.
Obstetrics-Gynecology & Women's Health
James Greenberg, MD, reviews the LaparoVue Visibility System, a single-use, disposable system designed to eliminate fogging while cleaning laparoscopes and trocars during a procedure.
In the second part of Dr. Lockwood's editorial on opioids, he discusses steps that ob/gyns can take to help limit opioid use disorder in our pregnant and non-pregnant patients.
A collection of standards, guidelines, tools and articles for the OB managing postpartum hemorrhage.
According to a literature review, apart from the essential role that sex hormones play in modulating hypoactive sexual desire disorder (HSDD) through therapeutic interventions, a comprehensive understanding of the biologic mechanisms underlying the disorder is imperative.
In a new statement, the US Preventive Services Task Force (USPSTF) is recommending against ovarian cancer screening for women who have no symptoms and no hereditary cancer syndromes. Plus: Breast MRI screening results in higher biopsy rates, according to a study.
Higher levels of distress were linked to increased vaginal sexual symptoms, worry about dyspareunia, dissatisfaction with a relationship, and concerns about body image in a study looking at sexual well-being among cervical cancer survivors.
A collection of standards, guidelines, tools and articles for further reading on maternal mortality.
A lower-dose estradiol vaginal cream than is currently available in the United States was an effective and well-tolerated treatment for dyspareunia in postmenopausal women, according to a recent phase 3, randomized, multicenter, double-blind, placebo-controlled trial.
A 62-year-old woman presents for her annual gynecologic exam, stating that she has had a 4-month history of worsening vulvar pruritus. Can you make the correct diagnosis and treatment plan?